SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-23-001360
Filing Date
2023-07-25
Accepted
2023-07-25 16:04:01
Documents
6
Period of Report
2023-07-25

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 11516
2 PRESS RELEASE nymox_ex991.htm EX-99.1 1866
3 PRESS RELEASE nymox_ex992.htm EX-99.2 748
4 nymox_ex991img1.jpg GRAPHIC 259953
5 nymox_ex991img2.jpg GRAPHIC 243192
6 nymox_ex992img1.jpg GRAPHIC 308170
  Complete submission text file 0001640334-23-001360.txt   1132948
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 231108568
SIC: 2835 In Vitro & In Vivo Diagnostic Substances